31.83
-2.54 (-7.39%)
| Previous Close | 34.37 |
| Open | 33.83 |
| Volume | 519,311 |
| Avg. Volume (3M) | 601,083 |
| Market Cap | 1,555,837,696 |
| Price / Sales | 3.35 |
| Price / Book | 3.52 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2025 - 5 May 2025 |
| Profit Margin | -9.61% |
| Operating Margin (TTM) | -11.69% |
| Diluted EPS (TTM) | -0.950 |
| Quarterly Revenue Growth (YOY) | 16.60% |
| Total Debt/Equity (MRQ) | 16.60% |
| Current Ratio (MRQ) | 3.65 |
| Operating Cash Flow (TTM) | 12.20 M |
| Levered Free Cash Flow (TTM) | -10.42 M |
| Return on Assets (TTM) | -4.09% |
| Return on Equity (TTM) | -9.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Bearish | Mixed | |
| Stock | AtriCure, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 3.49% |
| % Held by Institutions | 98.00% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (JMP Securities, 88.50%) | Buy |
| Median | 50.00 (57.09%) | |
| Low | 45.00 (Oppenheimer, 41.38%) | Buy |
| Average | 50.29 (58.00%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 36.99 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 28 Mar 2025 | 52.00 (63.37%) | Buy | 31.83 |
| 13 Feb 2025 | 66.00 (107.35%) | Buy | 39.59 | |
| JP Morgan | 27 Mar 2025 | 46.00 (44.52%) | Buy | 34.37 |
| 11 Feb 2025 | 51.00 (60.23%) | Buy | 41.51 | |
| Needham | 27 Mar 2025 | 51.00 (60.23%) | Buy | 34.37 |
| 21 Mar 2025 | 51.00 (60.23%) | Buy | 33.54 | |
| JMP Securities | 13 Feb 2025 | 60.00 (88.50%) | Buy | 39.59 |
| 10 Feb 2025 | 60.00 (88.50%) | Buy | 42.02 | |
| Oppenheimer | 13 Feb 2025 | 45.00 (41.38%) | Buy | 39.59 |
| Piper Sandler | 13 Feb 2025 | 50.00 (57.08%) | Buy | 39.59 |
| Stifel | 13 Feb 2025 | 48.00 (50.80%) | Buy | 39.59 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Mar 2025 | Announcement | AtriCure to Host Analyst & Investor Day on March 26, 2025 |
| 12 Feb 2025 | Announcement | AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results |
| 22 Jan 2025 | Announcement | AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results |
| 13 Jan 2025 | Announcement | AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |